We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-17.49%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.12B
AUM Growth
-$643M
Cap. Flow
-$73.8M
Cap. Flow %
-3.48%
Top 10 Hldgs %
32.59%
Holding
150
New
6
Increased
39
Reduced
39
Closed
17

Top Buys

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$41.3M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$26.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$12.3M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$30.7M
2
MOH icon
Molina Healthcare
MOH
+$26.6M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$17.3M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.6M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$15.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.36%
2 Consumer Staples 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.68B
$8.68M 0.41%
136,000
-29,000
-18% -$2.16M
ZGNX
77
DELISTED
Zogenix, Inc.
ZGNX
$8.57M 0.4%
235,000
– –
ZLAB icon
78
Zai Lab
ZLAB
$2.62B
$8.13M 0.38%
350,000
– –
GH icon
79
Guardant Health
GH
$22.6B
$8.12M 0.38%
+216,000
New +$7.96M
IFRX icon
80
InflaRx
IFRX
$271M
$7.92M 0.37%
217,900
+40,400
+23% +$1.24M
TBIO
81
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$7.57M 0.36%
1,009,179
– –
FRPT icon
82
Freshpet
FRPT
$3.22B
$7.56M 0.36%
+235,000
New +$8.18M
SRGA
83
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$7.21M 0.34%
65,000
– –
NVCR icon
84
NovoCure
NVCR
$1.91B
$6.53M 0.31%
195,000
+170,000
+680% +$6.22M
MRTX
85
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$6.36M 0.3%
150,000
-90,000
-38% -$3.59M
ODT
86
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.27M 0.3%
445,000
+9,500
+2% +$148K
CHRS icon
87
Coherus Oncology
CHRS
$196M
$6.06M 0.29%
670,000
– –
AXNX
88
DELISTED
Axonics, Inc. Common Stock
AXNX
$6.04M 0.29%
+400,000
New +$5.95M
NVAX icon
89
Novavax
NVAX
$1.31B
$5.98M 0.28%
162,500
– –
CO
90
DELISTED
Global Cord Blood Corporation
CO
$5.97M 0.28%
925,000
– –
PTLA
91
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$5.86M 0.28%
300,000
-23,800
-7% -$489K
RYTM icon
92
Rhythm Pharmaceuticals
RYTM
$7.96B
$5.82M 0.27%
216,500
+1,500
+0.7% +$41.5K
MYOV
93
DELISTED
Myovant Sciences Ltd.
MYOV
$5.7M 0.27%
347,500
– –
BCRX icon
94
BioCryst Pharmaceuticals
BCRX
$2.4B
$5.65M 0.27%
700,000
– –
APTX
95
DELISTED
Aptinyx Inc. Common Stock
APTX
$5.04M 0.24%
305,000
– –
SYRE icon
96
Spyre Therapeutics
SYRE
$9.25B
$4.87M 0.23%
26,000
– –
CBAY
97
DELISTED
Cymabay Therapeutics
CBAY
$4.83M 0.23%
613,604
– –
FPRX
98
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$4.7M 0.22%
505,000
-93,000
-16% -$1.11M
SAGE
99
DELISTED
Sage Therapeutics
SAGE
$4.69M 0.22%
49,000
– –
CLVS
100
DELISTED
Clovis Oncology, Inc.
CLVS
$4.6M 0.22%
256,000
-15,100
-6% -$309K
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Rock Springs Capital Management held 150 positions worth $2.12B, down 23% from $2.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $73.8M in Q4 2018, closing 17 positions and reducing 39 holdings. Its most notable exit was AbbVie, an estimated $30.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 90% a quarter earlier, followed by Consumer Staples.

Against the trend, Rock Springs Capital Management opened a new position in Seagen Inc. Common Stock worth $11.5M.

  • Rock Springs Capital Management's largest Q4 2018 buy was Seagen Inc. Common Stock: 202,500 shares worth $11.5M.
  • Rock Springs Capital Management added most to Wellcare Health Plans, Inc. in Q4 2018, an estimated $41.3M increase.
  • Rock Springs Capital Management's biggest Q4 2018 reduction was Molina Healthcare, cutting an estimated $26.6M.
  • Rock Springs Capital Management fully exited AbbVie in Q4 2018, selling an estimated $30.7M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $2.12B portfolio in Q4 2018.
  • Rock Springs Capital Management opened 6 new positions and closed 17 in Q4 2018.
  • Rock Springs Capital Management's portfolio value fell 23% quarter-over-quarter to $2.12B.

Based on Rock Springs Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.